- Home
- BMEA vs HYPR Comparison
BMEA vs HYPR Comparison
Compare BMEA & HYPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- HYPR
- Stock Information
- Founded
- BMEA 2017
- HYPR 2014
- Country
- BMEA United States
- HYPR United States
- Employees
- BMEA N/A
- HYPR N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- HYPR Medical Specialities
- Sector
- BMEA Health Care
- HYPR Health Care
- Exchange
- BMEA Nasdaq
- HYPR Nasdaq
- Market Cap
- BMEA 65.8M
- HYPR 54.6M
- IPO Year
- BMEA 2021
- HYPR N/A
- Fundamental
- Price
- BMEA $1.81
- HYPR $0.70
- Analyst Decision
- BMEA Strong Buy
- HYPR Strong Buy
- Analyst Count
- BMEA 10
- HYPR 3
- Target Price
- BMEA $22.30
- HYPR $1.06
- AVG Volume (30 Days)
- BMEA 5.2M
- HYPR 6.3M
- Earning Date
- BMEA 07-30-2025
- HYPR 08-07-2025
- Dividend Yield
- BMEA N/A
- HYPR N/A
- EPS Growth
- BMEA N/A
- HYPR N/A
- EPS
- BMEA N/A
- HYPR N/A
- Revenue
- BMEA N/A
- HYPR $11,732,000.00
- Revenue This Year
- BMEA N/A
- HYPR $12.31
- Revenue Next Year
- BMEA N/A
- HYPR $29.29
- P/E Ratio
- BMEA N/A
- HYPR N/A
- Revenue Growth
- BMEA N/A
- HYPR 0.34
- 52 Week Low
- BMEA $1.29
- HYPR $0.53
- 52 Week High
- BMEA $13.07
- HYPR $1.90
- Technical
- Relative Strength Index (RSI)
- BMEA 44.35
- HYPR 48.37
- Support Level
- BMEA $2.24
- HYPR $0.68
- Resistance Level
- BMEA $3.08
- HYPR $0.74
- Average True Range (ATR)
- BMEA 0.40
- HYPR 0.12
- MACD
- BMEA -0.03
- HYPR -0.01
- Stochastic Oscillator
- BMEA 25.07
- HYPR 18.33
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.